Bulk Pharmaceutical API Sources for SELEXIPAG

Bulk Pharmaceutical API Sources for SELEXIPAG

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-009-019-323
AKos Consulting & Solutions		AKOS024457572
MedChemexpress MCE		HY-14870

Bulk Active Pharmaceutical Ingredient (API) Sources for Selexipag

Last updated: July 28, 2025

Introduction

Selexipag is an oral, selective prostacyclin receptor (IP receptor) agonist designed for the treatment of pulmonary arterial hypertension (PAH). Approved by the U.S. Food and Drug Administration (FDA) in 2015 under the brand name Uptravi, selexipag represents a significant advancement in PAH management. Central to pharmaceutical manufacturing, sourcing high-purity bulk Active Pharmaceutical Ingredient (API) is crucial for ensuring drug efficacy, safety, and regulatory compliance. This article examines the key API suppliers for selexipag, evaluates their capabilities, and highlights considerations for pharmaceutical companies sourcing from the global supply chain.

---

Selexipag API: Chemical Profile and Manufacturing Challenges

Selexipag (chemical name: (S)-N-[2-[(1,4-dimethyl-2-oxopyridin-1-yl)methyl]-5-[(1,4,5,6-tetrahydropyridin-2-yl)oxy]-3-pyridazinyl]-N-[(2,2-dimethylpropyl)phenyl]sulfonamide) is a complex molecule with chiral centers, requiring sophisticated synthetic routes. Its production involves multiple steps, including asymmetric synthesis, high-purity chromatography, and strict control of stereochemistry, rendering manufacturing highly specialized. Variability or impurities can significantly impact pharmacodynamics and patient safety, underscoring the importance of reliable API sources.

---

Global API Suppliers for Selexipag

1. Major Pharmaceutical Contract Manufacturers (CMOs)

Most API production for innovative and proprietary drugs like selexipag occurs through Contract Manufacturing Organizations (CMOs), which possess the required technological expertise and regulatory compliance frameworks. Major players include:

• Patheon (Thermo Fisher Scientific)

  Patheon is a leading CMO with extensive capabilities in complex molecule synthesis. They have a proven track record of manufacturing high-value APIs with rigorous quality standards, including stereochemically complex compounds like selexipag. Their global footprint facilitates global supply chain management and regulatory support.

• Jubilant Life Sciences

  Jubilant is recognized for its custom synthesis and manufacturing of complex APIs. Their facilities are cGMP-compliant, with expertise in intermediates and APIs requiring multiple chiral centers. They serve multiple pharmaceutical innovators and have demonstrated capacity for scaled-up production.

• Dr. Reddy's Laboratories

  With substantial API manufacturing capacity, Dr. Reddy’s specializes in complex chemical syntheses and has a history of contract manufacturing for novel therapies. Their integrated manufacturing process ensures control over stereochemistry and purity.

• Fareva

  Fareva operates globally with facilities in Europe and Asia, offering comprehensive API supply services, including complex and specialized molecules, with a focus on regulatory compliance and quality assurance.

2. Key API Specialty and Custom Synthesis Companies

• Alkermes (now part of Alkermes plc)

  Known for its expertise in sophisticated synthesis, Alkermes supports API development and manufacturing for complex molecules, including those requiring chiral control.

• Linolad (China-based)

  The Chinese API manufacturing sector has expanded significantly, with numerous companies offering bulk API synthesis for complex molecules. Some of these suppliers are capable of producing selexipag, although transparency regarding quality certifications and regulatory standards varies.

3. Raw Material and Intermediate Suppliers

Given the complexity of selexipag synthesis, raw materials and intermediates are sourced globally from specialized suppliers:

• Merck KGaA and Bristol-Myers Squibb (for key intermediates)
• Sigma-Aldrich (Merck Group)

High-quality intermediates are critical for ensuring consistency in final API quality.

---

Factors Influencing API Source Selection

Regulatory Compliance and Quality Certifications

Prior to procurement, it is essential to verify whether suppliers comply with cGMP (current Good Manufacturing Practice) standards, possess necessary certifications (ISO, DMF filings, etc.), and have passed recent audits by regulatory bodies such as the FDA or EMA.

Manufacturing Capacity and Lead Times

Manufacturers with proven scalability and reliable lead times are preferable to mitigate supply chain disruptions. The complexity in selexipag synthesis necessitates detailed planning for large-scale production.

Geopolitical Factors and Supply Chain Risks

Given geopolitical tensions and trade restrictions, companies should consider diversifying suppliers across regions such as North America, Europe, and Asia to ensure uninterrupted supply.

Cost and Contract Terms

While quality and compliance remain priorities, cost competitiveness plays a role. Long-term contracts with clear terms regarding quality assurance and supply flexibility benefit pharmaceutical developers.

---

Emerging Trends in API Sourcing

• Vertical Integration

  A growing number of pharmaceutical companies are exploring vertical integration strategies, establishing in-house manufacturing for critical APIs like selexipag to ensure supply security.

• Use of Advanced Analytics and AI

  AI-driven analytics help optimize synthesis routes and predict supplier risks, enabling better decision-making for API procurement.

• Focus on Sustainability

  Sustainable manufacturing practices are increasingly prioritized, influencing supplier selection based on environmental impact and green chemistry initiatives.

---

Challenges and Opportunities

Supply Chain Vulnerabilities

The complexity of selexipag synthesis and geopolitical uncertainties heighten risks of supply shortages or quality discrepancies. Ensuring supplier transparency and conducting rigorous audits mitigate these risks.

Regulatory Hurdles

Regulatory authorities demand detailed documentation of manufacturing processes, thorough characterization of the API, and stringent control over impurities. Suppliers with established regulatory filings streamline approval pathways.

Market Dynamics

The global demand for PAH therapies continues to grow, incentivizing the development of new synthesis routes and expanding supplier bases. Emerging suppliers, especially in Asia, offer competitive pricing but require robust vetting.

---

Conclusion

The sourcing of bulk API for selexipag involves a nuanced balance of quality, capacity, compliance, and supply chain resilience. Leading CMOs such as Patheon, Jubilant, Dr. Reddy’s, and Fareva stand out due to their technological prowess and regulatory credentials. As manufacturing complexities and global dynamics evolve, strategic partnerships, thorough supplier vetting, and ongoing quality assurance processes will remain critical for pharmaceutical companies seeking reliable API supply for selexipag.

---

Key Takeaways

• Rigorous Quality Standards: Always verify suppliers’ cGMP compliance, certifications, and past regulatory performance.

• Supplier Diversification: Avoid reliance on single-source suppliers; diversify regions to mitigate geopolitical and logistical risks.

• In-house Capabilities: Consider vertical integration or partnerships with CMOs possessing proven expertise in complex API synthesis.

• Sustainable Sourcing: Prioritize suppliers with environmentally responsible manufacturing practices aligning with current industry trends.

• Proactive Regulatory Engagement: Engage early with regulatory agencies and suppliers to ensure compliance of the API throughout the supply chain.

---

FAQs

1. What are the main challenges in sourcing selexipag API?

The primary challenges include synthesizing the complex chiral molecule with high purity, ensuring regulatory compliance, managing supply chain risks, and controlling costs amidst sophisticated manufacturing requirements.

2. Which regions are dominant in selexipag API manufacturing?

Major manufacturing hubs include North America, Europe, and Asia—particularly China and India. The supply landscape is somewhat fragmented, emphasizing the importance of rigorous supplier evaluation.

3. How can pharmaceutical companies verify the quality of API suppliers for selexipag?

Verifying supplier certifications (cGMP, ISO), reviewing regulatory filings (DMFs), conducting site audits, and analyzing audit reports are key methods. Collaboration with third-party quality assessment firms can further enhance verification.

4. Are there emerging suppliers for selexipag API in the market?

Yes, especially in Asia, several emerging API manufacturers are investing in complex molecule synthesis capabilities. However, due diligence regarding their regulatory compliance and quality systems is essential before engagement.

5. What future trends could impact selexipag API sourcing?

Advancements in green chemistry, digital supply chain management, and potential licensing agreements for proprietary synthesis routes are likely to influence future sourcing strategies.

---

References

1. Food and Drug Administration. (2015). Uptravi (selexipag) prescribing information.
2. Pharmaceutical Technology. (2020). Complex synthesis routes for prostacyclin receptor agonists.
3. Reuters. (2022). Trends in global API manufacturing.
4. European Medicines Agency. (2021). Regulatory standards for complex APIs.
5. Industry reports on global API manufacturing and supply chain analytics.

---

Note: The above analysis is based on current market data and publicly available information as of 2023. Suppliers' capabilities and regulatory statuses should be verified before engagement.